## 1 Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient

# 2 stratification

- Robert L Hollis<sup>1\*</sup>, Alison M Meynert<sup>2</sup>, Caroline O Michie<sup>3</sup>, Tzyvia Rye<sup>1</sup>, Michael Churchman<sup>1</sup>, Amelia
  Hallas-Potts<sup>1</sup>, Ian Croy<sup>1</sup>, W. Glenn McCluggage<sup>4</sup>, Alistair R W Williams<sup>5</sup>, Clare Bartos<sup>1</sup>, Yasushi Iida<sup>1,6</sup>,
  Aikou Okamoto<sup>6</sup>, Brian Dougherty<sup>7</sup>, J. Carl Barrett<sup>7</sup>, Ruth March<sup>8</sup>, Athena Matakidou<sup>9</sup>, Patricia
  Roxburgh<sup>10,11</sup>, Colin A Semple<sup>2</sup>, D Paul Harkin<sup>12,13</sup>, Richard Kennedy<sup>12,13</sup>, C Simon Herrington<sup>1</sup> and
  Charlie Gourley<sup>1</sup>
- \*Correspondence: Dr Robb Hollis, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics
  and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XU, Scotland, UK.
  robb.hollis@ed.ac.uk

- <sup>1</sup>Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC
- 13 Institute of Genetics and Cancer, University of Edinburgh, UK
- 14 <sup>2</sup>MRC Human Genetics Unit, MRC Institute of Genetics and Cancer, University of Edinburgh, UK
- 15 <sup>3</sup>Edinburgh Cancer Centre, Western General Hospital, NHS Lothian, UK
- 16 <sup>4</sup>Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK
- 17 <sup>5</sup>Division of Pathology, The Royal Infirmary of Edinburgh, Edinburgh, UK
- 18 <sup>6</sup>The Jikei University School of Medicine, Tokyo, Japan
- 19 <sup>7</sup>Translational Medicine, Oncology R&D, AstraZeneca, Waltham, MA, USA
- 20 <sup>8</sup>Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK
- <sup>9</sup>Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca,
- 22 Cambridge, UK
- <sup>10</sup>Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, UK
- 24 <sup>11</sup>Beatson West of Scotland Cancer Centre, Glasgow, UK
- 25 <sup>12</sup>Almac Diagnostics, Craigavon, UK
- <sup>13</sup>Centre for Cancer Research and Cell Biology, Queen's University Belfast, UK
- 27 **COMELTA** is a batrant readers would be used to guide clinical practice.

## 28 ABSTRACT

Background: High grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer; most patients experience disease recurrence which accumulates chemoresistance, leading to treatment failure. Previous investigations have characterised HGSOC at the genomic and transcriptomic level, identifying subtypes of patients with differential outcome and treatment response. However, the relationship between molecular events identified at the gene sequence, gene copy number and gene expression levels remains poorly defined.

Methods: We perform multi-layer molecular characterisation of a large retrospective HGSOC cohort (n=362) with detailed clinical annotation to interrogate the relationship between patient groups defined by gene mutation, copy number events, gene expression patterns and infiltrating immune cell burden. We construct a high resolution picture of the molecular landscape in HGSOC and identify features of tumours associated with distinct clinical behaviour in patients.

40 **Results:** BRCA2-mutant (BRCA2m) and EMSY-overexpressing cases demonstrated prolonged survival 41 (multivariable hazard ratio 0.40 and 0.53) and higher chemotherapy response rates at first- and second-line treatment. CCNE1-gained (CCNE1g) cases demonstrated shorter survival (multivariable 42 43 hazard ratio 1.52, 95% CI 1.10-2.10), under-representation of FIGO stage IV cases (P=0.017) and no significant difference in treatment response. We demonstrate marked overlap between the TCGA-44 and derived subtypes: the TCGA DIF, IMR, PRO and MES subtypes correlated with the Tothill C4, C2, 45 46 C5 and C1 subtypes (P<0.001). IMR/C2 cases displayed higher BRCA1/2m frequency (25.5% and 32.5%) 47 and significantly greater infiltration of immune cells (P<0.001), while PRO/C5 cases had the highest CCNE1g rate (23.9% and 22.2%) and were uniformly low in immune cell infiltration. The survival 48 49 benefit for cases with aberrations in homologous recombination repair (HRR) genes was apparent 50 across all transcriptomic subtypes (hazard ratio range 0.48-0.68). There was significant co-occurrence of RB loss and HRR gene aberrations (P=0.005); RB loss was further associated with favourable survival 51 52 within cases harbouring HRR aberrations (multivariable hazard ratio 0.50, 95% CI 0.30-0.84).

Conclusions: These data paint a high resolution picture of the molecular landscape in HGSOC, better
 defining patients who may benefit most from specific molecular therapeutics and highlighting those
 for whom novel treatment strategies are needed to improve outcomes.

56 **Keywords**: high grade serous ovarian cancer, genomics, transcriptomics, survival, treatment response

57

# 58 1. BACKGROUND

High grade serous ovarian carcinoma (HGSOC) is the most common form of tubo-ovarian cancer. The majority of HGSOC patients are diagnosed at advanced stage and experience poor prognosis, with a five-year survival of approximately 30% in this population [1]. While the majority of HGSOC demonstrate high levels of intrinsic sensitivity to platinum-based chemotherapy, most patients experience disease recurrence which accumulates therapy resistance, leading to progressively shorter treatment-free intervals until patients eventually succumb to disease [2, 3].

65 In the hope of identifying therapeutically exploitable disease biology, a wealth of data have been 66 produced over the last two decades characterising the genomic and transcriptomic landscape of 67 HGSOC [4-7]. At the gene sequence level, identification of mutational disruption in BRCA1 and BRCA2 68 (BRCA1/2m) has ultimately paved the way for integration of poly-(ADP-ribose) polymerase (PARP) 69 inhibitor use into routine care for some patients [8-10]. Indeed, there continues to be an intense 70 research effort surrounding mechanisms and implications of homologous recombination DNA repair 71 (HRR) disruption beyond BRCA1/2m [11]; these include mutation of non-BRCA1/2 HRR genes [12], 72 large-scale genomic variants disrupting BRCA1/2 [13], epigenetic inactivation of HRR players such as BRCA1 and RAD51C [5, 14], and overexpression of the BRCA2 regulator EMSY [15, 16]. 73

At the gene expression level, numerous studies have characterised HGSOC samples, endeavouring to identify clinically meaningful transcriptomic subtypes of disease or expression signatures predictive of survival risk [4, 5, 7, 17, 18]. Most notably, Tothill et al. [4] and the TCGA investigators [5] each identified multiple transcriptomic subtypes, associating these with differential survival profiles. These

analyses have identified favourable outcome in patients with tumours harbouring expression profiles
suggestive of active immune engagement (TCGA IMR subtype [5, 19], Tothill C2 subtype [4]) –
consistent with earlier reports of favourable outcome in cases with high levels of cytotoxic T cell
infiltration [20, 21]. However, transcriptomic subtyping is not currently used for clinical
prognostication or stratification of HGSOC patients, despite some investigators reporting differential
sensitivity of these groups to agents such as bevacizumab [22].

84 While multiple investigators have characterised either the genomic or transcriptomic landscape of 85 HGSOC, few have investigated the relationship between genomic and transcriptomic features. Moreover, the relationship between these events and recently identified recurrent disruption of RB 86 87 and PTEN in HGSOC is poorly understood [6]. Integration of multiple layers of molecular 88 characterisation is required to paint a granular picture of the molecular landscape in HGSOC to better 89 inform rationally designed trials of novel treatment regimens or combination therapy strategies. 90 Indeed, some investigators have suggested that transcriptomic subtypes of HGSOC that appear to 91 derive greatest benefit from anti-angiogenic agents may be depleted for BRCA1/2m cases who benefit 92 most from PARP inhibition [5, 22]. This notion is consistent with mixed results observed from the 93 addition of anti-angiogenic agents to PARP inhibitors (PARPi) dependent on patient selection, therapy 94 line and agent combinations [23], exemplifying the need for comprehensive multi-layer molecular 95 characterisation to inform patient selection for future investigations of novel treatment approaches.

Here we perform matched genomic and transcriptomic characterisation of a large, well annotated
HGSOC cohort, dissecting the relationship between patient groups defined at the gene sequence, gene
copy number and gene expression level.

99

# 100 2. METHODS

#### 101 2.1 Patient cohort

102 539 ovarian cancer patients treated at the Edinburgh Cancer Centre met the following study inclusion 103 criteria: primary ovarian, peritoneal or fallopian tube carcinoma (any histological type) diagnosed prior 104 to 2007; available formalin-fixed paraffin-embedded (FFPE) treatment-naïve surgical specimen; first-105 line platinum-containing chemotherapy; minimum 3-year follow-up. Pathology review of H&E-stained 106 slides was undertaken by expert gynaecological pathologists (WGM, ARWW, CSH) to identify HGSOC 107 cases (figure S1); immunohistochemistry (IHC) for p53 and WT1 was used to clarify cases of uncertain 108 histological type (HGSOC: WT1 positive, p53 aberrant mutation-type expression pattern) 109 (Supplementary Methods Section 1) (figure S1). Ethical approval was obtained from South East 110 Scotland Human Annotated Bioresource (Lothian NRS Bioresource Ethics Committee reference 111 15/ES/0094-SR705 and SR752). The need for consent was waived by the ethics committee due to the 112 retrospective nature of the study.

### 113 2.2 Genomic characterisation

H&E stained slides were marked to identify tumour areas of high cellularity and used as a guide for
macrodissection of 10µm FFPE sections for DNA extraction. DNA extraction was performed using the
QIAamp FFPE DNA Kit and Qiagen Deparaffinisation Solution (Qiagen). Extracted DNA was quantified
by high sensitivity Qubit assay. *CCNE1* and *EMSY* copy number (CN) were quantified by TaqMan qPCR
(Supplementary Methods Section 2).

119 High throughput sequencing was performed using a custom Integrated DNA Technologies (IDT) gene 120 capture panel with unique molecular indices (UMIs) (Supplementary Methods Section 3). Whole 121 genome libraries were generated, pooled for target capture and sequenced using an Illumina NextSeq 122 550 at the Edinburgh Clinical Research Facility, Western General Hospital, Edinburgh, UK. The median 123 per-sample mean target coverage was 593X (range 205-3278X). Reads were processed using the bcbio 124 v1.0.6 high throughput sequence analysis pipeline (Supplementary Methods Section 4). Consensus reads aligned to hg38 underwent variant calling using a majority vote system from three variant callers 125 126 (Freebayes, VarDict and Mutect2). Called variants were annotated using the Ensembl VEP v90.9

- against Ensembl release 90 and filtered to retain only functional variation (Supplementary MethodsSection 5).
- 129 2.3 Transcriptomic subtyping
- 130 Transcriptomic data for the cohort were available from previous work identifying transcriptomic
- 131 subtypes of HGSOC [15, 17], including EMSY overexpression status (Supplementary Methods Section
- 132 6). TCGA (MES, PRO, IMR, DIF) and Tothill (C1, C2, C4, C5) transcriptomic subtyping calls were made
- 133 with the consensusOv R package using the consesusOv and Helland approaches [19] (Supplementary
- 134 Methods Section 6).
- 135 2.4 Immune cell infiltration analysis
- 136 Tumour infiltrating CD3-positive and CD8-positive immune cells were quantified by IHC of constructed
- 137 tumour tissue microarrays (TMAs) (Supplementary Methods Section 7); marker-positive cell burden
- 138 was quantified as percentage positive cells within tumour areas using QuPath version 0.1.2 [24].
- 139 2.5 Detection of PTEN and RB loss by immunohistochemistry
- 140 PTEN and RB protein loss was detected by IHC using sections of the HGSOC TMA (Supplementary
- 141 Methods Section 8). Loss was defined as complete absence of positive staining in tumour cells with
- 142 confirmed corresponding positive internal control stromal staining.
- 143 2.6 Copy number analysis from off-target sequencing reads

Copy number analysis was performed using CopywriteR [25] (Supplementary Methods Section 9): off target reads were used to estimate the relative copy number of 50kB genome segments across each chromosome, using the alignment bam files from the above sequencing analysis workflow. For quantification of CN alteration burden, adjacent 50kB segments of gain/loss representing the same large CN event were merged prior to quantification (Supplementary Methods Section 9).

149 2.7 Clinical annotation

Baseline clinicopathological features and outcome data were extracted from the Edinburgh Ovarian
Cancer Database [26], alongside chemotherapy response data (Supplementary Methods Section 10).
Overall survival (OS) and progression-free survival (PFS) were defined as the time from pathologically
confirmed diagnosis to patient death and disease progression or recurrence, respectively
(Supplementary Methods Section 9).

155 2.8 Statistical analyses

156 All statistical analyses were performed using R version 4.0.3 (R Foundation for Statistical Computing, 157 Vienna, Austria). Comparisons of frequency were performed using the Chi-squared test or Fisher's 158 exact test, as appropriate. Between-group comparisons of continuous variables was performed using 159 the Mann Whitney-U test. Survival analysis was performed using Cox proportional hazards regression 160 models and reported as hazard ratios (HR) with 95% confidence intervals (95% CI). For survival analysis 161 adjusted for other clinicopathological factors, multivariable hazard ratios (mHR) are reported. Median follow-up time was calculated by the reverse Kaplan-Meir method. Adjustment for multiple testing 162 163 was applied using the Bonferroni method.

164

# 165 **3. RESULTS**

166 3.1 Cohort characteristics

Of 539 ovarian cancer cases that met eligibility criteria, 362 were classified as HGSOC following
pathology review and underwent molecular characterisation (n=27 insufficient tumor, n=131 nonHGSOC, n=1 failed sequencing library preparation, n=8 failed quality control) (figure S1).
Clinicopathological features of the study cohort are summarised in table 1. The median follow-up time
was 15.0 years.

172 3.2 Molecular landscape of high grade serous ovarian carcinoma

The frequency of *TP53* mutation was 98.1% (355 of 362 cases) (figure 1, table S1). 12.7% and 6.6% of cases harboured *BRCA1*m and *BRCA2*m. Eight cases (2.2%) demonstrated mutation of other HRR genes (3 *BRIP1*, 2 *CHEK2*, 1 *RAD51C*, 1 *PALB2*, 1 concurrent *BAP1* and *NBN*). 14.9% of cases displayed CN gain of *CCNE1* (*CCNE1g*) and 6.6% demonstrated amplification of *EMSY*. Tumours demonstrating *EMSY* amplification were enriched for *EMSY* mRNA-overexpressing cases (P<0.001) (Supplementary table 2); however, *EMSY* CN was a poor predictor of *EMSY* overexpression status (positive predictive value 0.42, 95% CI 0.22-0.63; negative predictive value 0.88, 95% CI 0.84-0.91).

180 An HRR-centric stepwise taxonomy was constructed (figure 2A). Compared to the non-CCNE1g HRR-181 wild-type reference population (HRRwt, 55.8% of cases), BRCA2m and EMSY-overexpressing (8.6%) 182 cases demonstrated favourable outcome (mHR for OS = 0.40, 95% CI 0.25-0.65 and 0.53, 95% CI 0.33-183 0.84) (figure 2A, figure S2). Stage IV cases were under-represented in the CCNE1g group (8.2% vs 23.4% in the HRRwt group, P=0.017); CCNE1g cases demonstrated significantly shorter survival after 184 185 accounting for age, stage and debulking status (mHR for OS = 1.52, 95% CI 1.10-2.10). The BRCA2m 186 and EMSY-overexpressing subgroups demonstrated the highest rates of complete response to first 187 and second-line chemotherapy as determined by radiology or CA125 tumour marker (figure 2C). 188 Complete response rate was higher in the BRCA2m, EMSY-overexpressing and BRCA1m cases 189 compared to the HRRwt cases at first chemotherapy (P<0.001, P=0.009 and P=0.049 for complete 190 GCIG CA125 response [confirmed normalisation from at least double upper limit of normal]); however, 191 only BRCA2m and EMSY-overexpressing cases had a significantly higher complete response rate after 192 adjusting for multiple testing (P-adj=0.001, P-adj=0.027, P-adj=0.148). At relapse, BRCA2m and EMSY-193 overexpressing cases retained a higher chemotherapy response rate (P=0.002 and P=0.037 for 194 complete CA125 response, respectively). Chemotherapy response rate was similar in the CCNE1g and 195 HRRwt groups at both primary treatment and relapse (figure 2C).

196 *3.3 Relationship between transcriptomic subtypes* 

197 Two transcriptomic subtyping approaches were used (TCGA subtypes: DIF, IMR, PRO, MES; Tothill 198 subtypes: C1, C2, C4, C5). There was marked overlap between the subtyping approaches (P<0.0001) 199 (figure 3A): PRO cases were overwhelmingly of the C5 subtype (91.0%, 61 of 67), while the vast 200 majority of MES cases were of the C1 subtype (88.9%, 88 of 99). The DIF group comprised mainly C4 201 tumours (69.6%, 71 of 102), while IMR cases were mostly of the C2 subtype (66.0%, 62 of 94).

- 202 *3.4 Genomic-transcriptomic correlates*
- 203 There was marked association between HRR-centric and transcriptomic subtypes (figure 3B and 3C).

204 Frequency of BRCA1 and BRCA2 mutation differed significantly between transcriptomic subtypes, with

the highest and lowest *BRCA1/2*m rates in the IMR/C2 and PRO/C5 subtypes, respectively (25.5% and

32.5% vs 6.0% and 8.6%, P-adj=0.009 and 0.003) (figure 3B and 3C). Frequency of *CCNE1*g was highest
in PRO/C5 tumours (23.9% in PRO, 22.2% in C5), while the C2 subtype demonstrated the lowest

208 *CCNE1*g frequency (8.8%, P=0.002) (figure 3B and 4C).

Prolonged survival for HRR deficient cases was apparent across all transcriptomic subtypes (HR range
0.48-0.68) (figure S3 and S4). We did not observe any significant differences in overall burden of CN
loss or gain events between transcriptional subtypes (figure S5).

# 212 3.5 Immune cell infiltration burden

The burden of tumour-infiltrating CD3+ and CD8+ cells was heterogeneous across samples, with higher infiltration associated with prolonged survival (figure S6). *BRCA2*m cases demonstrated the highest levels of CD3+ infiltration (figure 4A).

Subtypes defined by both transcriptomic subgrouping methodologies demonstrated marked differences in infiltrating CD3+ (P-adj<0.0001) (figure 4B and 4C) and CD8+ cells (P-adj<0.0001) (figure S7). The IMR/C2 subtypes demonstrated the highest infiltration levels, while the PRO/C5 subtypes demonstrated uniformly low levels of infiltrating cells.

220 3.6 RB and PTEN loss in HGSOC

10.6% of cases (37 of 350 evaluable tumours) demonstrated PTEN protein loss (figure 1, figure 5A).
PTEN loss was a rare event in tumours of the PRO/C5 subtypes (3.0% in PRO, 2.5% in C5) (figure S9A and S9B). Cases with loss of PTEN expression demonstrated significantly lower *PTEN* CN (P=0.0003) (figure S9A).

16.8% of cases (59 of 352 evaluable tumours) demonstrated loss of RB protein (figure 1, figure S8C and S8D). RB loss was ubiquitous among HGSOCs harbouring *RB1* mutation (11/11 cases demonstrating loss; P<0.001 vs 48/341 in the absence of *RB1* mutation) (figure 1). Cases demonstrating RB loss had a lower *RB1* CN (P=0.0258) (figure S9B) and there was significant cooccurrence between RB loss and PTEN loss (22.8% PTEN loss in RB-lost cases, 13/57 vs 7.7%, 22/285 evaluable cases; P=0.001) (figure 1).

RB loss was significantly enriched among cases with HRR gene aberrations (*BRCA1m*, *BRCA2m*, *EMSY*overexpression or non-*BRCA*-HRR mutation) (26.0%, 27/104 evaluable cases vs 12.9%, 32/248;
P=0.005) (figure 5A) and was a rare event among *CCNE1*g cases (5.7%). In cases with HRR gene
aberrations, RB loss was associated with significantly longer survival (mHR for OS=0.50, 95% CI 0.300.84) (figure 5B); conversely, RB loss was not associated with significant differences in survival within
the remaining population (mHR=0.71, 95% CI 0.53-1.06) (figure 5B).

237

# 238 4. DISCUSSION

Substantial advancements in our understanding of HGSOC biology have been made over the last two decades, with many studies characterising HGSOC cases at the gene sequence and gene expression level [4-6, 19]. These investigations have identified subgroups of patients with differential outcome and therapy sensitivity, paving the way for molecular stratification of HGSOC patient care [8, 22, 27-29]. However, the relationship between features described at the genomic and transcriptomic level is poorly understood. We present matched genomic-transcriptomic characterisation – alongside

identification of other molecular features, including RB expression loss, PTEN expression loss, and
immune cell infiltration – in a large pathologically-confirmed HGSOC cohort with detailed clinical
annotation and extensive follow-up, revealing marked correlation across these levels of molecular
characterisation.

We utilised two transcriptomic subtyping approaches within our dataset: there was substantial correlation between TCGA (PRO, MES, DIF, IMR) and Tothill (C1, C2, C4, C5) subtypes. The MES and PRO TCGA subtypes demonstrated marker overlap with the C1 and C5 Tothill subtypes, while the majority of DIF and IMR cases were of the C4 and C2 subtypes, respectively. This overlap is consistent with previous reports of overlap between these subtyping approaches [19].

254 When comparing genomic features of these subtypes, the IMR/C2 groups demonstrated enrichment 255 for BRCA1/2m. These cases also demonstrated the highest immune cell infiltration burden, with 256 significantly greater levels of CD3+ and CD8+ cell infiltration. Together, the high BRCA1/2m rate and 257 high levels of immune engagement in IMR/C2 tumours likely underpin the favourable outcome 258 reported in these patient groups [19, 28]. In contrast, the vast majority of PRO/C5 cases were BRCA1/2 259 wild-type, and instead demonstrated the highest rates of CCNE1g; the PRO/C5 subtypes may therefore 260 represent the group least likely to benefit from PARP inhibition. Previous reports have suggested that 261 PRO cases may derive greatest benefit from anti-angiogenic agents such as bevacizumab [22]; the low 262 BRCA1/2m rate in this group may support the use of these agents over PARPi in this patient group. 263 Conversely, the IMR/C2 group harbour a large number of BRCA1/2m patients that are likely to benefit 264 from PARPi. Some investigators have suggested that anti-angiogenic therapies may not confer 265 greatest benefit in patients with HGSOC demonstrating immune-related gene expression signatures 266 [17], or may not benefit some groups of HRR-deficient patients [15, 30, 31]. Together, these data 267 suggest that further dissection of the relationship between transcriptional subtypes, HRR status and 268 relative benefit of single versus combined PARPi/anti-angiogenic strategies is required.

PRO/C5 cases were also uniformly low in tumour-infiltrating CD3+ and CD8+ cells, suggesting poor engagement of the immune system against the tumour within this patient group; this may partially account for the shorter survival time previously described in these cases [19, 28]. These data suggest that immune checkpoint inhibitors, currently under investigation in ovarian cancer, are also unlikely to represent viable therapeutic options for improving survival time in these patients [32].

274 Our multi-layer characterisation also sheds further light upon HRR pathway players and their 275 importance in HGSOC. We show that EMSY-overexpressing cases appear BRCA2m-like in their survival 276 profile and therapy sensitivity – consistent with EMSY's role as a BRCA2 regulator [16]. However, they 277 do not appear to be over-represented in the IMR/C2 transcriptomic subtypes, and do not demonstrate 278 a higher burden of tumour-infiltrating immune cells. We also demonstrate the importance of 279 aberrations in HRR genes regardless of the transcriptional subtype context; the hazard ratio for cases 280 with HRR gene aberrations ranged between 0.48-0.68 across all transcriptional subtypes. These data 281 confirm that the survival benefit among patients with tumours displaying HRR gene aberrations is not due to differential distribution of transcriptional subtypes. 282

283 CCNE1g has been the focus of intense research interest since its identification as a recurrent event in 284 HGSOC [5, 33-36]. A number of studies have suggested that cases harbouring CCNE1g have poorer 285 survival, with some suggesting this is due to greater intrinsic chemoresistance [5, 33-35]. However, 286 these comparisons have typically been made against the wider non-CCNE1g population without 287 accounting for HRR-deficiency, which is associated with longer survival and increased platinum 288 sensitivity, confounding these comparisons. We compare the CCNE1g population directly to non-289 CCNE1g HHRwt cases. CCNE1g was not associated with significantly poorer response rate to first-line 290 chemotherapy, or chemotherapy for relapsed disease, within our cohort. We show that, although the 291 most advanced stage cases are under-represented in the CCNE1g group, CCNE1g cases demonstrate 292 shorter survival time and that their survival is significantly poorer compared to non-CCNE1g HRRwt 293 patients upon multivariable analysis. CCNE1g tumours also demonstrated the lowest levels of

294 infiltrating immune cells compared to the other HRR-centric groups, which may contribute toward the 295 shorter patient survival time. Mutual exclusivity of CCNE1g and HRR gene events suggests that the 296 former are likely to represent a patient group who benefit least from PARP inhibition. Moreover, the 297 low immune infiltration levels demonstrated by these cases suggests that immune checkpoint 298 inhibitors are unlikely to be effective in these patients [32]. Given that CCNE1g is most frequent in the 299 PRO/C5 transcriptomic subtypes [22], and that the PRO subtype has been associated with greatest 300 benefit from bevacizumab in some reports, CCNE1g cases may represent those likely to derive benefit 301 from anti-angiogenic therapies. CCNE1g cases - alongside other HRR-proficient patient groups -302 represent HGSOC patients with shorter survival time for which new treatment approaches are needed 303 to improve survival. However, the low frequency of other molecular events in CCNE1g cases (BRCA1/2 304 wild-type, RB intact, PTEN intact, low immune cell infiltration), represents a challenge toward 305 identifying further candidate biologically-targeted strategies within this patient group. Inhibition of 306 WEE1 kinase represents a potential strategy of interest for CCNE1g cases, with recent data demonstrating objective responses to WEE1 inhibitors in treatment-refractory CCNE1g HGSOC [37]. 307

308 Disruption of *PTEN* and *RB1* have only recently been identified as highly recurrent events in HGSOC 309 [6]. The relationship of these events to other molecular features and their impact on patient outcome 310 is poorly understood. We demonstrate that PTEN and RB protein loss are neither mutually exclusive 311 with one another, nor mutually exclusive with other recurrent genomic events in this tumour type. 312 Indeed, the frequency of RB loss was significantly higher in HRR-deficient cases and there was 313 significant co-occurrence between RB and PTEN loss. By contrast, RB loss was a rare event in CCNE1g 314 cases. Cases with RB or PTEN loss demonstrated reduced CN at their respective loci; however, not all 315 cases with loss demonstrated low CN, suggesting mechanisms of inactivation beyond CN loss, 316 consistent with reports of complex structural variants (SVs) affecting both RB1 and PTEN [6]. Perhaps 317 most interestingly, RB status discriminated outcome within the cases showing HRR gene aberrations, 318 with the RB loss significantly associated with longer survival; RB-loss did not significantly impact 319 outcome in cases without identifiable events in HRR genes. It is unclear whether this phenotype is due

to differences in therapy sensitivity, or whether concurrent RB loss results in HRR-aberrant tumours
 with more indolent behaviour. Mechanistic work investigating the phenotypic and signalling
 consequences of RB loss in the context of HRR-deficiency is now warranted, including investigation of
 the relative chemosensitivity of RB-lost and RB-intact HRR-deficient cells.

324 We present a large, pathologically-confirmed HGSOC patient cohort with extensive follow-up and 325 detailed clinical annotation, including chemotherapy response data. Together with the multiple layers 326 of molecular characterisation, these represent major strengths of this work. However, we were unable 327 to characterise genome-wide SVs due to a lack of whole genome sequencing, which is a limitation of 328 the study. Lack of BRCA1/2 SV and BRCA1 promoter methylation data will have likely resulted in a 329 more conservative HR estimate when comparing our HRR-aberrant and HRRwt populations. SVs such 330 as translocations and inversions are known to affect NF1 in a proportion of HGSOC patients [6], and 331 we were unable to characterise this patient group in our study. Future work should seek to provide 332 even greater resolution within the HRR-proficient patient population, including characterisation of 333 cases with NF1 loss.

### 334 5. CONCLUSION

335 Together, these data provide a high resolution picture of the molecular landscape in HGSOC, 336 integrating genomic sequencing with copy number data, transcriptomic profiling and immune cell 337 infiltration burden in a cohort of HGSOC with rich clinical annotation. Specific transcriptomic subtypes 338 are associated with marked differences in frequency of HRR gene aberrations, CCNE1g and infiltration 339 of immune cells; integration of these data highlights patient groups most likely to responding to conventional chemotherapy and targeted biological therapeutics. Patients with CCNE1g and HRRwt 340 341 tumours represent those with greatest unmet clinical need; investigations of new treatment strategies 342 should focus on this patient group. RB and PTEN loss are common in HGSOC and frequently occur alongside other molecular events, with RB loss affecting a large number of tumours with HRR gene 343 344 aberrations.

## 345 Funding

346 RLH was supported by an MRC-funded fellowship (I171113-1019) and received funding from Target 347 Ovarian Cancer, Tenovus Scotland (E19-11) and the Nicola Murray Foundation during the course of 348 this work. AMM and CAS received core funding from the UK Medical Research Council to the MRC 349 Human Genetics Unit (MC\_UU\_00007/16). COM received funding from The Melville Trust for Care and 350 Cure of Cancer. Sample collection was supported by Cancer Research UK Experimental Cancer 351 Medicine Centre funding. TR was supported by core funding from CRUK awarded to the CRUK 352 Edinburgh Centre. The genomic characterisation of this cohort was funded by a research grant from 353 AstraZeneca.

# 354 Authors' contributions

355 RLH: conceptualisation, formal analysis, investigation, methodology, visualisation, writing – original 356 draft. AMM: methodology, investigation, writing - review and editing. COM: data curation, resources, 357 writing - review and editing. TR: data curation, investigation, writing - review and editing. MC: data 358 curation, project administration, writing – review and editing. AHP: investigation, writing – review and 359 editing. IC: investigation, writing - review and editing. WGM: investigation, writing - review and 360 editing. ARWW: investigation, writing – review and editing. CB: data curation, writing – review and 361 editing. YI: investigation, writing – review and editing. AO: supervision, writing – review and editing. 362 BD: methodology, writing – review and editing. JCB: conceptualisation, supervision, writing – review 363 and editing. RM: conceptualisation, supervision, writing – review and editing. AM: conceptualisation, 364 supervision, writing - review and editing. PR: conceptualisation, supervision, writing - review and 365 editing. CAS: methodology, supervision, writing – review and editing. DPH: methodology, writing – 366 review and editing. RK: methodology, writing - review and editing. CSH: conceptualisation, 367 investigation, methodology, supervision, writing - review and editing. CG: conceptualisation, 368 methodology, funding acquisition, supervision, writing – review and editing.

# 369 Declaration of competing interests

370 RLH: consultancy fees from GSK outside the scope of this work. AMM: none. COM: none. TR: none. 371 MC: none. IC: none. AHP: none. WGM: none. ARWW: consultancy fees from Bayer and Mithra outside 372 the scope of this work. CB: none. YI: none. AO: none. BD, JCB, RM: employees and stockholders of 373 AstraZeneca. AM: employee and stockholder of AstraZeneca during the course of this work, and 374 employee of GSK. PR: grants from AstraZeneca during the conduct of this work, grants from AstraZeneca outside of this work, personal fees from AstraZeneca and GlaxoSmithKline/Tesaro 375 376 outside of this work. CAS: none. DPH and RK: employees of Almac Diagnostics. CSH: none. CG: grants 377 from AstraZeneca during the conduct of this study, personal fees from MSD, GSK, Tesaro, Clovis, Roche, Foundation One, Chugai, Takeda, Sierra Oncology and Cor2Ed outside the submitted work, 378 patents PCT/US2012/040805 issued, PCT/GB2013/053202 pending, 1409479.1 pending, 1409476.7 379 380 pending, and 1409478.3 pending.

381

## 382 Acknowledgements

We thank the patients who contributed to this study and the Edinburgh Ovarian Cancer Database from which the clinical data reported here were retrieved. We are grateful to the NRS Lothian Human Annotated Bioresource, NHS Lothian Department of Pathology and Edinburgh Experimental Cancer Medicine Centre for their support. We thank the Edinburgh Clinical Research Facility, Western General Hospital, Edinburgh, UK for their support with the high throughput sequencing described here.

388

389

#### 390 References

- 1. Irodi, A., et al., Patterns of clinicopathological features and outcome in epithelial ovarian 391 392 cancer patients: 35 years of prospectively collected data. BJOG: An International Journal of 393 Obstetrics & Gynaecology. n/a(n/a).
- 394 2. Pignata, S., et al., Treatment of recurrent ovarian cancer. Annals of Oncology, 2017. 28: p. 395 viii51-viii56.
- 396 3. Kuroki, L. and S.R. Guntupalli, Treatment of epithelial ovarian cancer. BMJ, 2020. 371: p. 397 m3773.
- 398 Tothill, R.W., et al., Novel molecular subtypes of serous and endometrioid ovarian cancer 4. 399 *linked to clinical outcome.* Clin Cancer Res, 2008. **14**(16): p. 5198-208.
- 400 5. Bell, D., et al., Integrated genomic analyses of ovarian carcinoma. Nature, 2011. 474(7353): p. 401 609-615.
- 402 6. Patch, A.M., et al., Whole-genome characterization of chemoresistant ovarian cancer. Nature, 403 2015. 521(7553): p. 489-94.
- 404 7. Waldron, L., et al., Comparative meta-analysis of prognostic gene signatures for late-stage 405 ovarian cancer. J Natl Cancer Inst, 2014. 106(5).
- 406 8. Moore, K., et al., Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian 407 Cancer. N Engl J Med, 2018.
- 408 9. Mirza, M.R., et al., Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian 409 Cancer. N Engl J Med, 2016. 375(22): p. 2154-2164.
- 410 10. Colombo, N. and J.A. Ledermann, Updated treatment recommendations for newly diagnosed 411 epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines. Annals of Oncology, 412 2021.
- 413 11. Gourley, C., et al., Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer 414 Gene-mutated ovarian tumours: definition of homologous recombination deficiency? Curr 415 Opin Oncol, 2020. 32(5): p. 442-450.
- 416 12. Walsh, T., et al., Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal 417 carcinoma identified by massively parallel sequencing. Proceedings of the National Academy 418 of Sciences, 2011. 108(44): p. 18032.
- 419 13. Ewing, A., et al., Structural Variants at the <em&gt;BRCA1/2&lt;/em&gt; Loci are a Common 420 Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. Clinical 421 Cancer Research, 2021.
- 422 14. Cunningham, J.M., et al., Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, 423 and RAD51C status. Sci Rep, 2014. 4: p. 4026.
- 424 15. Hollis, R.L., et al., High EMSY expression defines a BRCA-like subgroup of high-grade serous 425 ovarian carcinoma with prolonged survival and hypersensitivity to platinum. Cancer, 2019. 426 125(16): p. 2772-2781.
- 427 16. Hughes-Davies, L., et al., EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. 428 Cell, 2003. 115(5): p. 523-35.
- 429 Gourley, C., et al., Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a 17. 430 predictor of outcome following bevacizumab. Journal of Clinical Oncology, 2014. **32**(15\_suppl): 431 p. 5502-5502.
- 432 18. Talhouk, A., et al., Development and Validation of the Gene Expression Predictor of High-grade 433 Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clin Cancer Res, 2020. 26(20): p. 434 5411-5423.
- 435 19. Chen, G.M., et al., Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma. 436 Clin Cancer Res, 2018. 24(20): p. 5037-5047.
- 437 20. Zhang, L., et al., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N 438 Engl J Med, 2003. 348(3): p. 203-13.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.07.22268840; this version posted January 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- perpetuity. It is made available under a CC-BY 4.0 International license .
- 439 21. Sato, E., et al., Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory 440 T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A, 441 2005. 102(51): p. 18538-43.
- 442 22. Kommoss, S., et al., Bevacizumab May Differentially Improve Ovarian Cancer Outcome in 443 Patients with Proliferative and Mesenchymal Molecular Subtypes. Clin Cancer Res, 2017. 444 **23**(14): p. 3794-3801.
- 445 23. An, D., S. Banerjee, and J.M. Lee, Recent advancements of antiangiogenic combination 446 therapies in ovarian cancer. Cancer Treat Rev, 2021. 98: p. 102224.
- 447 24. Bankhead, P., et al., QuPath: Open source software for digital pathology image analysis. 448 Scientific Reports, 2017. 7(1): p. 16878.
- 449 25. Kuilman, T., et al., CopywriteR: DNA copy number detection from off-target sequence data. 450 Genome Biol, 2015. 16(1): p. 49.
- 451 26. Irodi, A., et al., Patterns of clinicopathological features and outcome in epithelial ovarian 452 cancer patients: 35 years of prospectively collected data. BJOG, 2020. 127(11): p. 1409-1420.
- 453 27. Ledermann, J., et al., Olaparib maintenance therapy in platinum-sensitive relapsed ovarian 454 cancer. N Engl J Med, 2012. 366(15): p. 1382-92.
- 455 28. Gourley, C., et al., Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a 456 predictor of outcome following bevacizumab. Journal of Clinical Oncology, 2014. **32**(15 suppl): 457 p. 5502.
- 458 29. Tan, D.S., et al., "BRCAness" syndrome in ovarian cancer: a case-control study describing the 459 clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 460 and BRCA2 mutations. J Clin Oncol, 2008. 26(34): p. 5530-6.
- 461 30. Lorusso, D., et al., Bevacizumab as maintenance treatment in BRCA mutated patients with 462 advanced ovarian cancer: A large, retrospective, multicenter case-control study. Gynecol 463 Oncol, 2020. 159(1): p. 95-100.
- 464 31. Liu, J.F., et al., A phase III study comparing single-agent olaparib or the combination of 465 cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-466 sensitive ovarian cancer. Journal of Clinical Oncology, 2020. 38(15\_suppl): p. 6003-6003.
- 467 Zamarin, D., et al., Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab 32. 468 for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. J Clin Oncol, 2020. 38(16): 469 p. 1814-1823.
- 470 Nakayama, N., et al., Gene amplification CCNE1 is related to poor survival and potential 33. 471 therapeutic target in ovarian cancer. Cancer, 2010. 116(11): p. 2621-34.
- 472 34. Etemadmoghadam, D., et al., Synthetic lethality between CCNE1 amplification and loss of 473 BRCA1. Proc Natl Acad Sci U S A, 2013. 110(48): p. 19489-94.
- 474 Etemadmoghadam, D., et al., Integrated genome-wide DNA copy number and expression 35. 475 analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin 476 Cancer Res, 2009. 15(4): p. 1417-27.
- 477 36. Sapoznik, S., et al., CCNE1 expression in high grade serous carcinoma does not correlate with 478 chemoresistance. Oncotarget, 2017. 8(37): p. 62240-62247.
- 479 37. Fu, S., et al., Abstract 974: Phase II trial of the Wee1 inhibitor adavosertib in advanced 480 refractory solid tumors with CCNE1 amplification. Cancer Research, 2021. 81(13 Supplement): 481 p. 974.

482

#### 484 Tables

#### Table 1. Clinicopathological features of high grade serous carcinoma 485

		Ν	%		
Total cases	Ν	362			
Age at diagnosis	Median years	61	Range 33-86		
FIGO stage at	I	15	4.3		
diagnosis	II	31	8.8		
		237	67.5		
	IV	68	19.4		
	NA	11	-		
RD following	No visible RD (0cm)	65	19.4		
surgical	Macro RD (0.1-2cm)	66	19.7		
debulking	Gross macro RD (≥2cm)	187	55.8		
	Macro RD of unknown size	17	5.1		
	Unknown	27	-		
First line	Single-agent platinum	217	59.9		
chemotherapy	Platinum-taxane combination	135	37.3		
	Other platinum-containing regimes	10	2.8		
Vital status at	Alive	36	9.9		
last follow-up	Deceased - died of OC	307	84.8		
	Deceased - other causes	19	5.2		
Median follow- up time	Years	15.0 (95	15.0 (95% Cl 12.8-19.9)		
Median PFS	Years	1.17 (95% Cl 1.09-1.28)			
Median OS	Years	2.60 (95% CI 2.40-3.07)			

486 FIGO, International Federation of Gynecology and Obstetrics; NA, not available; Macro, macroscopic;

487 RD, maximal residual disease diameter; OC, ovarian carcinoma

# 488 Figures

Mutation status	TP53 BRCA1 BRCA2 nBRCA-HRR <sup>1</sup> RB1 PTEN						
Copy number	CCNE1 EMSY	•					
mRNA expression	EMSY						
Protein loss	RB PTEN						
Immune infiltration	CD3+ CD8+						
Transcriptomic subtype	TCGA Tothill						
		Mutation status Missense Frameshift indel Nonsense Start lost	CCNE1 copy number Wild-type CCNE1 gain	EMSY expression Wild-type EMSY overexpression	RB loss ☐ Intact ☐ RB loss ☐ Not evaluable	TCGA subtypes DIF IMR MES	Tothill subtypes C1 C2 C4 C5
		Splice site In frame indel Wild-type	<ul> <li>EMSY copy number</li> <li>Wild-type</li> <li>EMSY amplification</li> </ul>	Immune infiltration Low Intermediate High	PTEN loss Intact PTEN loss Not evaluable		

# 489

490 Figure 1. Molecular landscape of high grade serous ovarian carcinoma. <sup>1</sup>Mutation in non-*BRCA1/2* homologous recombination repair (HRR) genes: 3 *BRIP1*, 2

491 *CHEK2*, 1 *RAD51C*, 1 *PALB2*, 1 concurrent *BAP1* and *NBN*. *CCNE1* copy number (CN) gain, ≥4 copies by Taqman CN assay. *EMSY* CN amplification, ≥6 copies by
 492 Taqman CN assay.



Figure 2. Homologous recombination repair pathway (HRR)-centric subtyping of high grade serous carcinoma. (A) HRR-centric classification taxonomy. (B)
 Overall survival profile of HRR-centric subtypes. (C) Chemosensitivity of HRR-centric subtypes at first-line treatment (left hand panels) and treatment for
 disease relapse (right hand panels) as determined by CA125 tumour marker (top panels) and radiology (bottom panels). *BRCA2m, BRCA2* mutant; *BRCA1* mutant; *EMSY*-overxp; overexpression of *EMSY*; *CCNE1*g, gain of *CCNE1*; HRRwt, non-*CCNE1*g homologous recombination proficient.



## 

Figure 3. Relationship between subgroups methodologies. (A) Comparison of transcriptomic subgrouping approaches: composition of Tothill subtypes across
 each of the TCGA subtypes; labelled P value represents comparison of Tothill subtype frequency across all TCGA subtypes by Chi-squared test. (B) Distribution
 of homologous recombination repair (HRR)-centric subtypes across each of the TCGA transcriptomic subtypes; labelled P value represents comparison of
 *BRCA1/2*m frequency across all groups by Chi-squared test; P-adj=0.009. (C) Distribution of homologous recombination repair (HRR)-centric subtypes across
 each of the Tothill transcriptomic subtypes; labelled P value represents comparison of *BRCA1/2*m frequency across all groups by Chi-squared test; P-adj=0.009. (C) Distribution of homologous recombination repair (HRR)-centric subtypes across
 each of the Tothill transcriptomic subtypes; labelled P value represents comparison of *BRCA1/2*m frequency across all groups by Chi-squared test; P-adj=0.003.
 *BRCA2m, BRCA2* mutant; *BRCA1* mutant; *EMSY*-overxp; overexpression of *EMSY*; nBRCA-HRRm, non-*BRCA1/2* HRR gene mutation; *CCNE1*g, gain of
 *CCNE1*; HRRwt, non-*CCNE1*g homologous recombination proficient.



- 509 Figure 4. Tumour-infiltrating immune cells across high grade serous carcinoma subtypes. (A) CD3+ infiltration across HRR-centric subtypes; labelled P value
- 510 represents comparison of BRCA2m and CCNE1g groups using the Mann Whitney-U test. (B) CD3+ infiltration across TCGA transcriptomic subtypes; labelled P
- value represents comparison of IMR and PRO groups using the Mann Whitney-U test. (C) CD3+ infiltration across Tothill transcriptomic subtypes; labelled P
   value represents comparison of C2 and C5 groups using the Mann Whitney-U test. BRCA2m, BRCA2 mutant; BRCA1m, BRCA1 mutant; EMSY-overxp;
- 513 overexpression of *EMSY*; *CCNE1*g, gain of *CCNE1*; HRRwt, non-*CCNE1*g homologous recombination proficient.



514

515 Figure 5. PTEN and RB loss in high grade serous ovarian carcinoma. (A) Frequency of loss of PTEN protein expression across homologous recombination repair

516 (HRR)-centric subtypes. (B) Frequency of loss of RB protein expression across homologous recombination repair (HRR)-centric subtypes. (C) Impact of RB loss 517 on survival in patients based on HRR status. Multivariable hazard ratio (mHR) for HRR-ab: RB-loss vs HRR-ab RB-intact=0.50, 95% CI 0.30-0.84; mHR for

518 HRRwt/CCNE1g: RB-loss vs HRRwt/CCNE1g: RB-intact=0.71, 95% CI 0.48-1.06. BRCA2m, BRCA2 mutant; BRCA1m, BRCA1 mutant; EMSY-overxp;

519 overexpression of *EMSY*; nBRCA-HRRm, non-*BRCA1/2* HRR gene mutation; *CCNE1*g, gain of *CCNE1*; HRRwt, non-*CCNE1*g HRR wild-type. HRR-ab, HRR-aberrant:

520 *BRCA1*m, *BRCA2*m, *EMSY*-overxp or n*BRCA*-HRRm.